Appetite Control Peptides

Regulates appetite and hunger

Primary Use

Appetite control peptides regulate hunger and satiety signals through gut-brain communication pathways. GLP-1 agonists (semaglutide, tirzepatide, liraglutide) are the most effective, working by mimicking a hormone your small intestine releases after eating that tells your brain you are full. They also slow gastric emptying, so food stays in your stomach longer, extending the feeling of satiety. MK-677, conversely, increases appetite through ghrelin receptor activation, which is useful for people trying to gain weight.

The ability to modulate appetite in either direction makes this category relevant for both weight loss and weight gain protocols. Understanding which direction a peptide pushes appetite is critical for choosing the right compound for your goal.

This page collects every peptide on PeptideWiki tagged for appetite control. Browse individual profiles for mechanisms, dosing, and safety data.

Peptides (8)

Retatrutide

Metabolic & Weight Loss

Retatrutide is an investigational medication that activates three hormone receptors (GIP, GLP-1, and glucagon) at the same time. Phase 2 trials showed up to 24% body weight loss at 48 weeks, and it is currently in Phase 3 development.

Semaglutide

Metabolic & Weight Loss

Semaglutide is a medication that mimics a natural fullness hormone (GLP-1) in the body. It is FDA-approved as Wegovy for weight management and Ozempic for type 2 diabetes, with significant effects on appetite control and blood sugar regulation.

Tirzepatide

Metabolic & Weight Loss

Tirzepatide is a dual-action medication that activates both GIP and GLP-1 receptors, two key fullness and blood sugar hormones. It is FDA-approved as Mounjaro for type 2 diabetes and Zepbound for weight management, outperforming semaglutide in head-to-head trials.

Melanotan II

Skin, Hair & Aesthetics

Melanotan II is a synthetic version of alpha-MSH, a natural hormone involved in skin pigmentation. It activates hormone receptors involved in skin color and sexual function, and is being studied for both tanning and sexual health applications.

Liraglutide

Metabolic & Weight Loss

Liraglutide is a medication that mimics a natural fullness hormone (GLP-1) in the body. It is FDA-approved as Victoza for type 2 diabetes and Saxenda for weight management, with an extensive record of clinical safety and effectiveness data.

Cagrilintide

Metabolic & Weight Loss

Cagrilintide is a long-acting amylin analogue, a once-weekly injection that mimics a natural fullness hormone to curb appetite and reduce body weight. It is studied both on its own and combined with semaglutide as CagriSema, which produced about 20 percent weight loss in late-stage trials. It is investigational and not yet approved.

Setmelanotide

Metabolic & Weight Loss

Setmelanotide (brand name Imcivree) is an FDA-approved injectable peptide that switches on a brain receptor controlling hunger. It is approved specifically for rare forms of severe obesity driven by the brain hunger pathway, not for general weight loss, and in trials it cut both hunger and body weight in those conditions.

Tesofensine

Metabolic & Weight Loss

Tesofensine is an oral weight-loss compound that blocks the brain from reabsorbing three appetite-related chemical messengers, noradrenaline, dopamine, and serotonin, so the feeling of fullness lasts longer and hunger drops. In a Phase 2 trial it produced about twice the weight loss of the diet drugs available at the time. It is investigational and not approved.

Frequently Asked Questions

GLP-1 (glucagon-like peptide-1) is naturally released by your gut after eating. It signals satiety centers in the hypothalamus and brainstem, reducing the urge to eat. GLP-1 agonist peptides mimic this hormone but last much longer (natural GLP-1 is degraded in minutes; semaglutide lasts about a week). They also slow gastric emptying, meaning food stays in your stomach longer and you feel full sooner during meals. The combined effect is reduced hunger between meals and smaller portion sizes at meals, both driven by biological signaling rather than willpower.

MK-677 (ibutamoren) is the primary appetite-stimulating peptide. It activates ghrelin receptors, mimicking the hunger hormone that rises before meals. This can be useful for people struggling to eat enough calories for muscle gain, recovery from illness, or age-related appetite loss. GHRP-6 also stimulates appetite through ghrelin pathways, though less potently than MK-677. GHRP-2 and ipamorelin have minimal appetite effects, making them better choices when appetite stimulation is not desired.

Some tolerance to the appetite-suppressing effects can develop, but clinical trials of semaglutide and tirzepatide showed sustained weight loss over 68-72 weeks, suggesting the effects remain clinically significant even if the initial dramatic appetite reduction softens somewhat. Dose escalation (starting low and increasing over weeks) is built into GLP-1 protocols partly to manage this. The nausea that many users experience initially also fades within the first weeks as the body adapts.

Semaglutide has shown benefit in reducing binge eating behaviors in clinical studies, likely because it reduces the neurological drive to eat rather than just the physical sensation of hunger. GLP-1 receptors exist in brain regions involved in food reward and compulsive eating, not just satiety centers. This suggests the effect goes beyond simple appetite suppression. However, binge eating disorder is a complex condition with psychological components that peptides alone cannot address. They are most effective as part of a comprehensive treatment plan.

Related Primary Use Tags

Weight Loss

Wound Healing

Muscle Recovery

Muscle Support

Growth Hormone

IGF-1 Elevation